Mizuho Reiterates Outperform Rating on Harmony Biosciences Holdings Inc. (HRMY)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Goldman Sachs Reiterates Sell Rating on Harmony Biosciences Holdings Inc. (HRMY)
October 2, 2024 5:37 AM EDTGoldman Sachs analyst Corinne Jenkins reiterated a Sell rating and $28.00 price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY)
The analyst comments "HRMY hosted its Investor Day (10/1) where the focus was on its three neurology franchises, including within (i) sleep/wake, (ii) neurobehavioral, and (iii) epilepsy verticals. The sleep/wake focus was... More
